Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-25T10:02:44.587Z Has data issue: false hasContentIssue false
  • English
  • Français

Topiramate in the Preventive Treatment of Episodic Migraine: A Combined Analysis From Pilot, Double-Blind, Placebo-Controlled Trials

Published online by Cambridge University Press:  07 November 2014

Keith R. Edwards ,
Doreen L. Potter ,
Shu-Chen Wu ,
Marc Kamin  and
Joseph Hulihan
Get access Rights & Permissions [Opens in a new window]

Abstract

The safety and efficacy of medications for preventive treatment of migraine is the subject of current concern and investigation in health care. Two single-center, double-blind, placebo-controlled studies were conducted to evaluate the efficacy and safety of topiramate for migraine prophylaxis. Seventy patients with a diagnosis of migraine were randomly assigned to topiramate-treated and placebo groups. The studies consisted of a 4-week baseline phase, a 6—8 week titration, and 8–12 weeks of maintenance. Topiramate was titrated from an initial dose of 25 mg/day to a target dose of 100 mg BID. The primary efficacy measure, the mean 28-day migraine frequency, was lower in topiramate-treated patients than in the placebo group (3.2 versus 3.8, P=.001). Similarly, topiramate treatment resulted in a significantly greater mean reduction in migraine frequency than did placebo (1.55 versus 0.47, P=.001) and a significantly higher responder rate (35.3% versus 8.3%, P=.008). Paresthesia was the most common side effect reported with topiramate treatment. Other topiramate-associated adverse events included altered taste, memory impairment, diarrhea, and appetite suppression/weight loss. The rates of discontinuation were similar for the topiramate group (n=10) and the placebo group (n=8). These results suggest that topiramate is effective and well tolerated in the preventive treatment of migraine headaches.

Type
Original Research
Information
CNS Spectrums , Volume 8 , Issue 6: Migraines: Neurological and Psychiatric Perspectives , June 2003 , pp. 428 - 432
Copyright
Copyright © Cambridge University Press 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Dahlof, CGH, Dimenas, E. Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia. 1995;15:31–36.CrossRefGoogle ScholarPubMed
2.Lipton, RB, Stewart, WF. Migraine headaches: epidemiology and comorbidity. Clin Neurosci. 1998;5:2–9.Google ScholarPubMed
3.Lipton, RB, Stewart, WF, Simon, D. Medical consultation for migraine: results from the American Migraine Study. Headache. 1998;38:87–96.CrossRefGoogle ScholarPubMed
4.Hu, XH, Markson, LE, Lipton, RB, Stewart, WF, Berger, ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159:813–818.CrossRefGoogle ScholarPubMed
5.Silberstein, SD, Lipton, RB, Goadsby, PJ. Headache in Clinical Practice. Oxford, England: Isis Medical Media Ltd.; 1998.Google Scholar
6.Edmeads, J, Findlay, H, Tugwell, P, Pryse-Phillips, W, Nelson, RF, Murray, TJ. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci. 1993;20:131–137.CrossRefGoogle ScholarPubMed
7.Duke University Center for Clinical Health Policy Research. Drug Treatments for the Prevention of Migraine Headache. Publication #290-94-2025 (Technical Review 2.3). Springfield, VA: U.S. Department of Commerce; 1999.Google Scholar
8.Moskowitz, MA, Macfarlane, R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev. 1993;5:159–177.Google ScholarPubMed
9.Welch, KM, D'Andrea, G, Tepley, N, Barkley, G, Ramadan, NM. The concept of migraine as a state of central neuronal hyperexcitability. Neurol Clin. 1990;8:817–828.CrossRefGoogle ScholarPubMed
10.Shank, RP, Gardocki, JF, Streeter, AJ, Maryanoff, BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(suppl 1):S3–S9.CrossRefGoogle ScholarPubMed
11.White, HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia. 1999;40(suppl 5):S2–10.CrossRefGoogle ScholarPubMed
12.Taverna, S, Sancini, G, Mantegazza, M, Franceschetti, S, Avanzini, G. Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther. 1999;288:960–968.Google ScholarPubMed
13.White, HS, Brown, SD, Woodhead, JH, Skeen, GA, Wolf, HH. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia. 2000;41(suppl 1):S17–S20.CrossRefGoogle ScholarPubMed
14.Shuaib, A, Ahmed, F, Muratoglu, M, Kochanski, P. Topiramate in migraine prophylaxis: a pilot study. Cephalalgia. 1999;19:379–380.Google Scholar
15.Krusz, JC, Scott, V. Topiramate in the treatment of chronic migraine and other headaches [abstract]. Headache. 1999;39:363.Google Scholar
16.Von Seggern, RL, Mannix, LK, Adelman, JU. Efficacy of topiramate in migraine prophylaxis: a retrospective chart analysis [abstract]. Neurology. 2000;54(suppl 3):A267–A268.Google Scholar
17.Storey, JR, Calder, CS, Hart, DE, Potter, DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache. 2001;41:968–975.CrossRefGoogle ScholarPubMed
18.Edwards, KR, Glantz, MJ, Norton, JA, Cross, N. Prophylactic treatment of episodic migraine with topiramate: a double-blind, placebo-controlled trial in 30 patients [abstract]. Cephalalgia. 2000;20:316.Google Scholar
19.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
20.Klapper, J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997;17:103–108.CrossRefGoogle ScholarPubMed
21.Silberstein, SD, Collins, SD. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Headache. 1999;39:633–643.CrossRefGoogle ScholarPubMed
22.Storey, JR, Calder, CS, Potter, DL. Role of topiramate for refractory migraine prophylaxis: a retrospective pilot study [abstract]. Ann Neurol. 2000;46:495.Google Scholar
23.Chengappa, KNR, Levine, J, Rathore, D, Parepally, H, Atzert, R. Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur Psychiatry. 2001;16:186–190.CrossRefGoogle Scholar
24.Edwards, KR, Glantz, MJ, Button, J. Efficacy and safety of topiramate in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study [abstract]. Neurology. 2000;54(suppl 3):A81.Google Scholar
25.Ben-Menachem, E, Smith, U, Hellstrom, K, Stagge, A. Predictors of weight loss in patients with epilepsy treated with topiramate [abstract]. Epilepsia. 2001;42(suppl 7):252.Google Scholar
26.Slater, JD, Reife, RA, Kamin, M. Weight changes in epilepsy patients treated with topiramate [abstract]. Neurology. 2002;58(suppl 3):A422.Google Scholar
27.Burstein, R, Collins, B, Jakubowski, M. Defeating migraine pain with triptans: a race against the developing allodynia [abstract]. Neurology. 2003;60(suppl 1):A92–A93.Google Scholar
28.Mathew, NT, Schmitt, J, Jacobs, D, Neto, W. Topiramate in migraine prevention (MIGR-001): effect on migraine frequency [abstract]. Neurology. 2003;60(suppl 1):A336.Google Scholar
29.Brandes, JL, Jacobs, D, Neto, W, Bhattacharaya, S. Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled, parallel study (MIGR-002) [abstract]. Neurology. 2003;60(suppl 1):A238.Google Scholar